Designing and in-vitro evaluation of gastro retentive drug delivery system for Pregabalin

International Journal of PharmTech Research

Volumn 4, Issue 3, 2012, Pages 1041-1049

  Ratnaparkhi, M P ^a   Bhabad, V S ^a   Chaudhari, S P ^a  

^a Marathwada Mitra Mandal's College of Pharmacy   (India)

Author keywords

Floating matrix; Gastroretentive; HPMC K4M; Pregabalin; Sustained release

Indexed keywords

CROSPOVIDONE; ETHYL CELLULOSE; HPMC K4M; POLYMER; PREGABALIN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL COMPOSITION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BUOYANCY DURATION; DRUG BUOYANCY LAG TIME; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG GRANULATION; DRUG RELEASE RATE; DRUG RELEASE RETARDING CAPACITY; DRUG RETENTION; DRUG SCREENING; DRUG STABILITY; DRUG SWELLING INDEX; DRUG WET GRANULATION; FLOATING MATRIX TABLET; IN VITRO STUDY; MATRIX TABLET; PHARMACOLOGICAL PARAMETERS; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; SUSTAINED RELEASE GASTRO RETENTIVE DRUG DELIVERY SYSTEM; UPPER GASTROINTESTINAL TRACT; VISCOSITY;

EID: 84870211456     PISSN: 09744304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. nd ed. Revised and Expanded, Drugs and Pharmaceutical Sciences, Volume-50, New York: Marcel Dekker Inc; 1992: 1-196.
2. st ed. New Delhi: Vallabh Prakashan; 1995: 335-357.
3. th ed. Pennsylvania: Mack Publishing Company; 2001: 903-929.
4. nd ed. New York: Livingstone Churchill Elsevier Science Ltd; 2002: 315-320.
5. st ed. New Delhi: Vallabh Prakashan; 2000: 1-6, 54, 155, 196.
6. st Reprint 2004 New Delhi: CBS Publisher and Distributor: 256.
7. Venkatraman S, Davar N, Chester A, Kleiner L. An overview of controlled release system. In: Wise DL, editor. Handbook of Pharmaceutical Controlled Release Technology. New York: Marcel Dekker Inc; 2000: 211, 431-463.
8. Doelkar E, Rouge N, Buri P. Drug absorption sites in the gastrointestinal tract and dosage forms for site specific delivery, Int J Pharm Sci 1996; 136(1-2): 117-139.
9. Hoffman A, Klausner EA, Lavy E, Friedman M. Expandable gastroretentive dosage forms. J Control Release 2003; 90: 143-162
10. Whitehead L, Fell JT, Collette JH, Sharma HJ, Smith AM.,Floating Dosage Forms: An in vivo study demonstrating prolonged gastric retention. J Control Release 1998; 55(1): 3-12.
11. Arora S, Ali J, Ahuja A, Khar RK, Baboota S., Floating Drug Delivery Systems: A Review. AAPS PharmSciTech 2005; 6(3): E372-E90.
12. Singh Sanjay Gastroretentive Drug Delivery System; Current Approaches Review. Article Journal of Pharmacy Research. 2009; 2(5): 881-886.
13. Kim KH, Singh BN., Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000; 63: 235-259.
14. Garg R, Gupta GD. Progress in controlled gastroretentive delivery systems. Tropical J Pharm Res. 2008; 7(3): 1055-1066.
15. Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR. Novel sustained release,swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int J Pharm. 2006; 316: 86-92.
16. st ed. New Delhi: CBS Publishers and Distributors; 2004: 76-97, 470-509.
17. st ed. New Delhi: CBS Publisher and Distributor; 2004:76-97.
18. Nayak A, Maji R, Das B. Gastroretentive Drug delivery systems: A Review article. Journal of Pharmacy Research. 2010; Vol.3 Issue 1:101-106.
19. th ed Available at: http://www.touchbrifings.com/cdps/cditem.cfm?NID-17&CID-5
20. Faivre V, Bardonnet PL, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: Overview and special case of Helicobacter pylori. J Control Release. 2006; 111: 1-18.
21. Park K, Chen J, Blevins WE, Park H. Gastric retention properties of superporous hydrogel composites. J Control Release. 2000; 64: 39-51.
22. Ito R, Machida Y, Sannan T, Nagai T. Magnetic granules: a novel system for specific drug delivery to esophageal mucosa in oral administration. Int J Pharm.1990; 61(2): 109-117.
23. Cargill R, Cadwell LJ, Engle K, Fix JA, Porter PA, Gardner CR. Controlled gastric emptying: I. Effects of physical properties on gastric residence times of nondisintegrating geometric shapes in beagle dogs. Pharm Res. 1988; 8(5): 533-536.
24. Maincent P, Kedzierewicz F, Thouvenot P, Lemut J, Etienne A, Hoffman M. Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy. J Control Release. 1999; 58(2): 195-205.
25. Timmermans J, Moes AJ. How well do floating dosage forms float? Int J Pharm. 1990; 62: 207-216.
26. Sheth PR, Tossounian J. The hydrodynamically balanced system, a novel drug delivery system for oral use. Drug Devlop Ind Pharm. 1984; 10: 313-339
27. Timmermans J, Andre JM. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy.J Pharm Sci.1994; 83: 392-397.
28. Elena M. Influence of the viscosity grade and particle size of HPMC on metronidazole release from matrix tablets. Eur J Pharm Biopharm. 1997;43: 173-178.
29. Talukdar MM, Mooter GV, Augustigins P, Tjandra MT, Verbeke N, Kinget R. In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation. Int J Pharma. 1998; 169: 105-113
30. Bodmeier R, Streubel A, Siepmann J. Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters on drug release. Eur J Pharm Sci. 2003; 18: 37-45.
31. K. Raghuram Reddy, Srinivas Mutalik, Srinivas Reddy.Once-daily Sustained release Matrix Tablets of Nidocranil: formulation & evalution. AAPS Pharmscitech. 2003; 4(4) article 61:1-9.
32. Dave B S, Amin A.F, Patel M.M. Gastroretentive Drug Delivery System of Ranitidine Hydrochloride: Formulation and In Vitro Evaluation. AAPS PharmSciTech. 2004; 5(2) Article 34:1-9
33. Shrivastava AK, Wadhava S, Ridhurkar D, Mishra B. Oral sustained delivery of atenolol from floating matrix tablets: Formulation and in vitro evaluation. Drug Dev Ind Pharm. 2005; 31: 367-374.